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Purpose: Spinal cord injury (SCI) is associated with permanent neurological dam-
age, and treatment thereof with a single modality often does not provide sufficient 
therapeutic outcomes. Therefore, a strategy that combines two or more techniques 
might show better therapeutic effects. Materials and Methods: In this study, we 
designed a combined treatment strategy based on neural stem cells (NSCs) introduced 
via a neuronal cell type‒inducible transgene expression system (NSE::) controlled 
by a neuron-specific enolase (NSE) promoter to maximize therapeutic efficiency 
and neuronal differentiation. The luciferase gene was chosen to confirm whether 
this combined system was working properly prior to using a therapeutic gene. The 
luciferase expression levels of NSCs introduced via the neuronal cell type‒induc-
ible luciferase expression system (NSE::Luci) or via a general luciferase expressing 
system (SV::Luci) were measured and compared in vitro and in vivo. Results: 
NSCs introduced via the neuronal cell type‒inducible luciferase expressing system 
(NSE::Luci-NSCs) showed a high level of luciferase expression, compared to 
NSCs introduced via a general luciferase expressing system (SV::Luci-NSCs). In-
terestingly, the luciferase expression level of NSE::Luci-NSCs increased greatly af-
ter differentiation into neurons. Conclusion: We demonstrated that a neuronal cell 
type‒inducible gene expression system is suitable for introducing NSCs in com-
bined treatment strategies. We suggest that the proposed strategy may be a promis-
ing tool for the treatment of neurodegenerative disorders, including SCI.
Key Words:   Neuronal cell type‒inducible transgene expression, neural stem cells, 
combined treatment strategy, spinal cord injury
INTRODUCTION
Spinal cord injury (SCI) is often associated with permanent disability as a result of 
sensory or motor functional defects caused by neuronal death and demyelination 
after primary physical damage.1 Treatment with a single modality is unlikely to re-
sult in complete recovery. Therefore, combined treatment might be effective for im-
proving therapeutic efficacy. In the field of gene therapy, therapeutic gene expres-
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basic vector (Promega, Cat.no E1751). The construction de-
signs of the plasmid are shown in Fig. 1. 
Cell culture
We used mouse NSCs in this study. NSCs (CRL-2925, ATCC, 
Manassas, VA, USA) were cultured in dulbecco’s modified 
eagle medium (DMEM)/F12 and supplemented with 10% 
fetal bovine serum (FBS; Thermo Scientific, Waltham, MA, 
USA) and 1% penicillin and streptomycin (Invitrogen, Carls-
bad, CA, USA). Approximately 4×105 cells were plated in 
six-well culture dishes (4×104 cells/cm2) and incubated at 
37°C in a humidified atmosphere containing 5% CO2. 
For the other experiment, we used the human embryonic 
kidney 293 cell (293FT) provided from Prof. Kang at Yon-
sei University. Cells were cultured in DMEM supplement-
ed with 10% FBS, 1% penicillin and streptomycin, 1X non-
essential amino acid (NEAA; Invitrogen), and 1X sodium 
pyruvate (Invitrogen). Approximately 6×105 cells were plat-
ed in six-well culture dishes (6×104 cells/cm2) and incubated 
at 37°C in a humidified atmosphere containing 5% CO2. 
Gene transfection
Transfection was performed using Lipofectamine 2000 (In-
vitrogen) as previously described.9 Briefly, NSE::Luci, SV:: 
Luci, or SV::DsRed (Control) plasmid (each 4 μg) were in-
dividually mixed with serum-free and antibiotic-free DMEM/ 
F12 medium. Lipofectamine (10 μL) also was mixed with 
serum-free and antibiotic-free DMEM/F12 medium. Plas-
mid DNA solution was mixed with the lipofectamine-
DMEM mixture and then incubated for 20 min at room tem-
perature (RT). The DNA-lipofectamine mixture was added 
to NSCs or 293FT cells, and the cells were incubated at 37°C 
in a humidified atmosphere containing 5% CO2. 
sion controlled by hypoxia-specific or tissue-specific gene 
expression systems offers a possibility for efficient and safe 
gene therapy.2-6 
In the stem cell therapy field, transplantation with neural 
stem cells (NSCs) showed therapeutic potential in animal 
models with incurable disorders, including SCI.7,8 Interest-
ingly, it has been reported that stem cells can be used as a 
gene delivery system9 and that stem cell‒mediated gene 
therapy results in a better therapeutic outcome and more sta-
ble therapeutic gene delivery than single therapy with stem 
cells or therapeutic genes alone.10-14 
Considering that most stem cell therapies for SCI have 
used NSCs or neural precursor cells, which have high neuro-
nal differentiation potentials, we chose a neuronal cell type‒
inducible transgene expression system (NSE::) for transgene 
overexpression in NSCs. We assumed that a combined treat-
ment strategy based on NSCs and an transgene expression 
system controlled by a neuron-specific enolase (NSE) pro-
moter would increase therapeutic efficiency. Finally, we 
demonstrated that it is suitable with NSCs for the establish-
ment of a gene and NSC therapy platform. 
MATERIALS AND METHODS
Plasmid construction
To confirm whether the NSE was suitable with NSCs for 
this combined treatment strategy, both a neuronal cell-type‒
inducible luciferase expression system (NSE::Luci) and a 
general luciferase expression system (SV::Luci) were made 
by pGL3 luciferase reporter vectors. SV::Luci was pur-
chased from Promega (Madison, WI, USA, Cat.no E1761). 
Neuron-specific enolase (NSE) promoter was provided by 
Prof. Lee at Hanyang University, Seoul, Korea. The NSE re-
gion was inserted between NheI and BglII sites of the pGL3-
Fig. 1. Plasmid construction. Plasmid construction of neuronal cell type–inducible (NSE::Luci) or general (SV::Luci) luciferase overexpression vector. The 
neuron-specific enolase (NSE) promoter region was inserted to pGL3-basic vector after digestion (NheI and BglII sites).
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Luciferase assays
A luciferase assay was performed 24‒48 hrs after gene 
transfection or cell transplantation, and each sample (cells or 
tissues) were lysed with Pro-prepTM (INTRON Biotechnol-
ogy, Gyeonggi, Korea). The concentration of protein in ly-
sates was measured using a bicinchoninic acid protein as-
say kit (Pierce, Iselin, NJ, USA), following the manufactur-
er’s protocol. Luciferase expression was measured using a 
luminometer for 10 s. The level of luciferase expression was 
expressed in relative light units (RLU) per mg of protein.
Immunocytochemistry
Differentiated cells were fixed in 4% paraformaldehyde, pH 
7.4 (Merck, Darmstadt, Germany), for 10‒15 min at RT. 
Samples were washed with phosphate buffered saline (PBS, 
Thermo) three times. Blocking was performed with 10% 
normal donkey serum in PBS containing 0.3% Triton X-100 
for 60 min at RT. Primary antibodies against beta-III-Tubu-
lin (TUJ1), microtubule-associated protein 2 (MAP2), neu-
ral cell adhesion molecule (NCAM), and neurofilament (NF) 
were incubated overnight at 4°C. Samples were washed three 
times with PBS, and secondary antibodies were added and 
incubated for 1 h at RT. Samples were washed three times 
with PBS, and 4’,6’-diamino-2-phenylinodole (DAPI; Vector 
Labs, Burlingame, CA, USA) was added. Samples were 
covered with glass coverslips. A confocal laser scanning mi-
croscope (LSM 700, Zeiss, Oberkochen, Germany) was 
used for analysis.
Statistical analysis
Statistical analysis was performed using Prism 6 (Graphpad, 
San Diego, CA, USA). All data were evaluated using Stu-
dent’s t-test and a one-way analysis of variance (ANOVA). 
All data are expressed as the mean±standard error of the 
mean. All p-values<0.05 were considered statistically sig-
nificant. 
RESULTS
 
Expression pattern of neural stem cells transfected with 
a neuronal cell-type‒inducible luciferase overexpression 
system (NSE::Luci-NSCs)
NSE::Luci was constructed using NSE promoter and pGL3-
basic plasmid (Fig. 1). To confirm whether this neuronal 
cell-type‒inducible gene overexpression system is suitable 
for NSCs, we investigated the expression level of luciferase 
Neural differentiation
For neural differentiation, NSCs were cultured in presence of 
retinoic acid (RA; Sigma, St. Louis, MO, USA) for 7 days. 
RA was dissolved in dimethyl sulfoxide (DMSO) (working 
solution, 10 mM) and diluted with culture media (final con-
centration, 0.01 μM, 0.1 μM, and 1 μM). Briefly, NSCs were 
seeded on poly-l-lysine (2 μg/cm2, Sigma)‒coated glass cov-
erslips at a density of 2×104 cells/cm2. After 24-h incubation, 
the medium was replaced with a complete medium with or 
without RA and then changed every 2 days. Neural differen-
tiation was carried out for 7 days. 
Cell transplantation
All protocols were approved by the Animal Care and Use 
Committee of the Medical Research Institute at Yonsei Uni-
versity College of Medicine. All experiments were conduct-
ed in accordance with international guidelines on the ethical 
use of animals, and the number of animals used was mini-
mized. For anesthesia, ICR mice (male, 6 weeks, 30 g, Ori-
entBio, Seongnam, Gyeonggi-do, Korea) were intraperito-
neally injected with ketamine (100 mg/kg, Yuhan, Seoul, 
Korea) and rompun (10 mg/kg, Bayer Korea, Seoul, Korea). 
Laminectomy was performed at thoracic level 11. SCI was 
carried out using self-closing forceps (compression injury for 
10 sec). Animals were divided into two groups, those treat-
ed with SV::Luci-NSCs and those treated with NSE::Luci-
NSCs. NSCs (5×105 cells/2 μL) were directly injected into 
the spinal cord using a microinjection pump (injection rate, 
1 μL/min). After transplantation, the exposure site was cl-
osed using suture wound clips. Cyclosporin A (10 mg/kg, 
Chong Kun Dang, Seoul, Korea) and cefazolin (20 mg/kg, 
Yuhan) were intraperitoneally injected daily.
In Vivo Imaging System (IVIS)
The In Vivo Imaging System (IVIS) Spectrum (Xenogen, Al-
ameda, CA, USA) was used to detect luciferase expression. 
For in vivo imaging, mice were anesthetized with ketamine 
(100 mg/kg) and rompun (10 mg/kg), and then the substrate 
D-luciferin (150 mg/kg) was injected intraperitoneally. Tw-
enty minutes after injection, bioluminescence images were 
captured for 10 min. Regions of interest (ROIs) were ana-
lyzed, and total quantification of bioluminescence was quan-
tified using Living Image® (Xenogen) software. For in vitro 
imaging, the substrate D-luciferin (150 μg/mL) was added to 
the SV::DsRed-NSCs (Control), SV::Luci-NSCs, or NSE::Luci-
NSCs in medium, followed by mounting and biolumines-
cence detection for 2‒3 min.
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cantly increased in NSE::Luci-NSCs, compared with that in 
SV::Luci-NSCs (Fig. 2). These results indicate that com-
bined therapy with NSCs and a neuronal cell type‒induc-
ible gene overexpression system can be applied to spinal 
cord injuries that cause tissue ischemia.
To confirm whether the NSE was selectively working in 
neuronal lineage cells, we examined the luciferase expres-
sion level in 293FT cells, non-neuronal cell, transfected with 
SV::DsRed (Control), SV::Luci, or NSE::Luci plasmid. We 
confirmed that the luciferase expression level in 293FT trans-
fected with NSE::Luci plasmid was significantly lower than 
293FT transfected with SV::Luci plasmid (Fig. 3). This re-
in NSCs transfected with SV::DsRed (Control), SV::Luci 
plasmid, and NSE::Luci plasmid. Based on the results of 
IVIS and the luciferase assay, we confirmed that luciferase 
expression significantly increased in NSE::Luci-NSCs, 
compared with SV::Luci-NSCs (Fig. 2). These results indi-
cate that the neuronal cell type‒inducible transgene overex-
pression system is suitable for NSCs. To confirm whether 
the transgene overexpression pattern can be sustained after 
hypoxic injury (mimicking tissue ischemia after SCI), we in-
vestigated the luciferase expression level of Control, SV::Luci-
NSCs, and NSE::Luci-NSCs after hypoxic injury for 24 h. 
We confirmed that the luciferase expression level signifi-
Fig. 2. Luciferase expression pattern of neural stem cells introduced with a neuronal cell type–inducible luciferase overexpression system (NSE::Luci-NSCs) in 
normoxia and hypoxia. Luciferase expression levels of Control, SV::Luci-NSCs, and NSE::Luci-NSCs examined by luciferase expression imaging at 24–48 h 
after transfection. (A) The result of luciferase expression imaging indicates that luciferase in NSE::Luci-NSCs group is highly over-expressed, compared to 
the other groups. The color scale bar indicates the luciferase expression level. (B) Quantitative analysis of luciferase expression imaging in (A). (C) 
Luciferase expression levels of Control, SV::Luci-NSCs, and NSE::Luci-NSCs examined by luciferase assay at 24–48 h after transfection. Luciferase expression 
of NSE::Luci-NSC is much higher than the other groups in normoxia and hypoxia. The number of the symbol indicates the value of n. Data are represented as 
mean±standard error of the mean. *p<0.05. ROI, regions of interest; NSC, neural stem cell; NSE, neuron-specific enolase; RLU, relative light units.
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ed for neuronal specific markers, such as TUJ1, MAP2, 
NCAM, and NF. We confirmed that differentiated cells were 
positive for all neuronal markers (Fig. 4), meaning that NSCs 
used in this experiment were efficiently differentiated into 
neurons.
To confirm whether the luciferase expression pattern of 
the NSE::Luci-NSCs can be increased after neuronal differ-
entiation (1 μM RA), compared with NSC stage (0 μM RA), 
we investigated the luciferase expression level at the stage 
of NSCs and differentiated neurons after transfection with 
NSE::Luci or SV::Luci plasmids. We confirmed that the lu-
ciferase expression level of NSCs transfected with NSE:: 
Luci plasmid was much higher after neuronal differentia-
tion (Fig. 5A). At the neuronal differentiation condition (1 
μM RA), the luciferase expression level of NSE::Luci-NSCs 
was significantly higher than that of SV::Luci-NSCs (Fig. 5B).
These results mean that the transgene expression by NSE 
promoter was induced by neuronal differentiation. Thus, 
these findings indicate that the neuronal cell-type‒inducible 
transgene overexpression system appropriates with NSCs, 
which have a neuronal differentiation potency for combined 
treatment strategies. 
Transgene expression pattern in vivo
To confirm whether NSE::Luci-NSCs show a consistent 
sult means that the efficacy of the neuronal cell type‒induc-
ible gene expression system depends on neuronal lineage 
cell type.
Transgene expression pattern in differentiated neurons
To confirm the differentiation potency of NSCs, neural dif-
ferentiation was induced by RA treatment. Differentiated 
cells cultured in the presence of 1 μM RA for 7 d were stain-
Fig. 3. Neuronal cell-type–inducible luciferase gene overexpression systems 
in non-neuronal cells. Luciferase expression levels of SV::Luci-293FT and 
NSE::Luci-293FT confirmed by luciferase assay at 48 h transfection. The 
number of the symbol indicates the value of n. Data are represented as 
mean±standard error of the mean. *p<0.05. NSE, neuron-specific enolase; 
RLU, relative light units.
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cells (used as a mean non-neuronal cell type) transfected 
with NSE::Luci plasmid was significantly lower than that 
of 293FT cells transfected with SV::Luci plasmid. This re-
sult means that transgene overexpression by NSE promoter 
is already working at the NSC stage. A previous study in-
vestigated the difference of gene overexpression based on 
NSE promoter between neurons and non-neuronal cells, 
such as HEK293 and HeLa cells; however, the study did not 
examine the difference of gene overexpression at the NSC 
stage.4 Thus, we carefully suggest that neuron-specific pro-
moter may function extensively in neuronal lineage cells in-
cluding NSCs.
Additionally, we confirmed that NSE::Luci-NSCs show-
ed a higher luciferase expression level than the SV::Luci-
NSCs under normoxia and hypoxia, and the luciferase ex-
pression level of NSE::Luci-NSCs was much higher after 
differentiation into neurons. All of these features can be used 
advantageously, if the luciferase used in this study were to 
be replaced by other therapeutic genes. 
In our previous study, we confirmed that a NSCs transfect-
ed with a hypoxia-inducible gene expression system should 
be maintained for at least 1 day under hypoxic conditions 
for transgene overexpression.9 However, the gene expres-
sion level of NSCs transfected with a neuronal cell type‒in-
ducible gene overexpression system was sufficiently greater 
in normoxia, namely before transplantation (saving time, as 
there is no need to wait 1 day). Thus, the high amount of se-
high expression pattern in vivo, both SV::Luci-NSCs and 
NSE::Luci-NSCs were transplanted into the spinal cord, 
and an IVIS analysis and luciferase assay was carried out 
24‒48 h after transplantation. Similar to our results in vitro, 
the luciferase expression level was significantly higher in 
NSE::Luci-NSCs than in SV::Luci-NSCs (Fig. 6). These 
results indicate that a combined treatment strategy based on 
a neuronal cell type‒inducible transgene expression system 
and NSCs can be applied to SCI.
DISCUSSION
As one of the pathologies that appear after SCI, an ischemic 
environment in the spinal cord is caused by the destruction 
of blood vessels; this ischemic condition lasts from several 
days to several weeks. The survival rate of stem cells trans-
planted into the ischemic environment would normally rap-
idly decline. For the protection of transplanted stem cells 
and the injured spinal cord, we designed a gene and stem 
cell therapy platform based on NSCs and a neuronal cell 
type‒inducible gene expression system. 
Gene overexpression by NSE promoter is already known 
to work in mature neurons. However, we confirmed that the 
luciferase expression level of NSE::Luci-NSCs was signifi-
cantly higher than the luciferase expression level of SV:: 
Luci-NSCs, and the luciferase expression level of 293FT 
Fig. 5. High luciferase expression pattern after differentiation into neurons. (A) The luciferase expression level in neural stem cells and differentiated neu-
rons was compared by luciferase assay. Luciferase expression is significantly greater in differentiated neurons (with RA) than in neural stem cells (without 
RA).  (B) The luciferase expression level of NSE::Luci-NSCs after neuronal differentiation is significantly greater than that of SV::Luci-NSCs after differentia-
tion. The number of the symbol indicates the value of n. Data are represented as mean±standard error of the mean. *p<0.05. RA, retinoic acid; NSC, neural 
stem cell; NSE, neuron-specific enolase; RLU, relative light units.
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inducible therapeutic gene overexpression system and NSCs 
may be a promising tool for the treatment of SCI.
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